- Author
- Rein Verbeke (UGent) , Miffy H.Y. Cheng and Pieter C. Cullis
- Organization
- Abstract
- The rapid development of mRNA vaccines against COVID-19 was made possible by the cumulative knowledge and advancements across multiple scientific fields. This chapter aims to explain the key milestones on the journey toward safe and effective mRNA vaccine products and covers three main aspects: (i) the discovery, in vitro production, and optimization of mRNA as a therapeutic modality, (ii) the search for a suitable vehicle that could enable the efficient and safe delivery of intact mRNA inside cells, with an emphasis on the development of the LNP technology, and (iii) the clinical progress of mRNA vaccines starting with the first proof-of-concept studies that demonstrated the rationale of using mRNA for vaccination, followed by how mRNA vaccine design clinically evolved over more than two decades of development.
Downloads
-
(...).docx
- full text (Accepted manuscript)
- |
- UGent only
- |
- Word
- |
- 499.32 KB
Citation
Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-01JJRX6E4CF1F60B3YBDAKBAC8
- MLA
- Verbeke, Rein, et al. “A Historical Overview on MRNA Vaccine Development.” Trends in MRNA Vaccine Research, edited by Gabor Tamas Szabo and Norbert Pardi, Wiley-VCH, 2025, pp. 1–27, doi:10.1002/9783527838394.ch1.
- APA
- Verbeke, R., Cheng, M. H. Y., & Cullis, P. C. (2025). A historical overview on mRNA vaccine development. In G. T. Szabo & N. Pardi (Eds.), Trends in mRNA vaccine research (pp. 1–27). https://doi.org/10.1002/9783527838394.ch1
- Chicago author-date
- Verbeke, Rein, Miffy H.Y. Cheng, and Pieter C. Cullis. 2025. “A Historical Overview on MRNA Vaccine Development.” In Trends in MRNA Vaccine Research, edited by Gabor Tamas Szabo and Norbert Pardi, 1–27. Weinheim: Wiley-VCH. https://doi.org/10.1002/9783527838394.ch1.
- Chicago author-date (all authors)
- Verbeke, Rein, Miffy H.Y. Cheng, and Pieter C. Cullis. 2025. “A Historical Overview on MRNA Vaccine Development.” In Trends in MRNA Vaccine Research, ed by. Gabor Tamas Szabo and Norbert Pardi, 1–27. Weinheim: Wiley-VCH. doi:10.1002/9783527838394.ch1.
- Vancouver
- 1.Verbeke R, Cheng MHY, Cullis PC. A historical overview on mRNA vaccine development. In: Szabo GT, Pardi N, editors. Trends in mRNA vaccine research. Weinheim: Wiley-VCH; 2025. p. 1–27.
- IEEE
- [1]R. Verbeke, M. H. Y. Cheng, and P. C. Cullis, “A historical overview on mRNA vaccine development,” in Trends in mRNA vaccine research, G. T. Szabo and N. Pardi, Eds. Weinheim: Wiley-VCH, 2025, pp. 1–27.
@incollection{01JJRX6E4CF1F60B3YBDAKBAC8,
abstract = {{The rapid development of mRNA vaccines against COVID-19 was made possible by the cumulative knowledge and advancements across multiple scientific fields. This chapter aims to explain the key milestones on the journey toward safe and effective mRNA vaccine products and covers three main aspects: (i) the discovery, in vitro production, and optimization of mRNA as a therapeutic modality, (ii) the search for a suitable vehicle that could enable the efficient and safe delivery of intact mRNA inside cells, with an emphasis on the development of the LNP technology, and (iii) the clinical progress of mRNA vaccines starting with the first proof-of-concept studies that demonstrated the rationale of using mRNA for vaccination, followed by how mRNA vaccine design clinically evolved over more than two decades of development.}},
author = {{Verbeke, Rein and Cheng, Miffy H.Y. and Cullis, Pieter C.}},
booktitle = {{Trends in mRNA vaccine research}},
editor = {{Szabo, Gabor Tamas and Pardi, Norbert}},
isbn = {{9783527350582}},
language = {{eng}},
pages = {{1--27}},
publisher = {{Wiley-VCH}},
title = {{A historical overview on mRNA vaccine development}},
url = {{http://doi.org/10.1002/9783527838394.ch1}},
year = {{2025}},
}
- Altmetric
- View in Altmetric